389 related articles for article (PubMed ID: 23903326)
21. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
Varenhorst C; James S; Erlinge D; Braun OO; Brandt JT; Winters KJ; Jakubowski JA; Olofsson S; Wallentin L; Siegbahn A
Am Heart J; 2009 Mar; 157(3):562.e1-9. PubMed ID: 19249429
[TBL] [Abstract][Full Text] [Related]
22. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
23. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
van Giezen JJ; Berntsson P; Zachrisson H; Björkman JA
Thromb Res; 2009 Nov; 124(5):565-71. PubMed ID: 19692114
[TBL] [Abstract][Full Text] [Related]
24. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
[TBL] [Abstract][Full Text] [Related]
25. Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.
Spiel AO; Derhaschnig U; Schwameis M; Bartko J; Siller-Matula JM; Jilma B
Clin Sci (Lond); 2012 Nov; 123(10):591-600. PubMed ID: 22646240
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).
Angiolillo DJ; Curzen N; Gurbel P; Vaitkus P; Lipkin F; Li W; Jakubowski JA; Zettler M; Effron MB; Trenk D
J Am Coll Cardiol; 2014 Apr; 63(15):1500-9. PubMed ID: 24333493
[TBL] [Abstract][Full Text] [Related]
27. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
[TBL] [Abstract][Full Text] [Related]
28. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects.
Jakubowski JA; Payne CD; Brandt JT; Weerakkody GJ; Farid NA; Small DS; Naganuma H; Li GY; Winters KJ
J Cardiovasc Pharmacol; 2006 Mar; 47(3):377-84. PubMed ID: 16633079
[TBL] [Abstract][Full Text] [Related]
29. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
30. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Gurbel PA; Bliden KP; Butler K; Antonino MJ; Wei C; Teng R; Rasmussen L; Storey RF; Nielsen T; Eikelboom JW; Sabe-Affaki G; Husted S; Kereiakes DJ; Henderson D; Patel DV; Tantry US
Circulation; 2010 Mar; 121(10):1188-99. PubMed ID: 20194878
[TBL] [Abstract][Full Text] [Related]
31. Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats.
Sugidachi A; Yamaguchi S; Jakubowski JA; Ohno K; Tomizawa A; Hashimoto M; Niitsu Y
J Cardiovasc Pharmacol; 2011 Sep; 58(3):329-34. PubMed ID: 21697729
[TBL] [Abstract][Full Text] [Related]
32. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
33. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers.
Hobl EL; Reiter B; Schoergenhofer C; Schwameis M; Derhaschnig U; Kubica J; Stimpfl T; Jilma B
Eur J Clin Invest; 2016 Jan; 46(1):7-14. PubMed ID: 26449338
[TBL] [Abstract][Full Text] [Related]
34. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
[TBL] [Abstract][Full Text] [Related]
35. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
[TBL] [Abstract][Full Text] [Related]
36. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Niitsu Y; Jakubowski JA; Sugidachi A; Asai F
Semin Thromb Hemost; 2005 Apr; 31(2):184-94. PubMed ID: 15852222
[TBL] [Abstract][Full Text] [Related]
37. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
Jakubowski JA; Winters KJ; Naganuma H; Wallentin L
Cardiovasc Drug Rev; 2007; 25(4):357-74. PubMed ID: 18078435
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Yokoi H; Kimura T; Isshiki T; Ogawa H; Ikeda Y
Thromb Res; 2012 May; 129(5):623-8. PubMed ID: 22178576
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
[TBL] [Abstract][Full Text] [Related]
40. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG
J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
